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Abstract 
In the present study we evaluated the in vitro and in vivo degradation of an in situ forming biodegradable implant. For this 
purpose we used a poly(D,L-lactide-co-glycolide) (PLGA) polymer dissolved in biocompatible solvent dimethylsulfoxide 
(DMSO). The evolution of the morphology, mass loss, water gain, hollow fraction, and molecular weight of the implants 
degraded in both conditions was investigated and compared. Implants presented a porous morphology, being denser and 
having channels in vivo, as seen by scanning electron microscopy. Erosion in vivo of implants involved the appearance of 
new small pores, while an increase of the size of preexisting pores was seen in vitro. Mass loss and molecular weight as a 
measure of erosion and degradation, respectively  decreased much faster in vivo than in vitro, suggesting the importance 
of environmental conditions on these processes of porous biodegradable matrices formed in situ. 
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1. Introduction 
Some injectable fluid systems are capable of form in situ polymeric matrices. These systems are useful for 
the entrapment and controlled release of drugs and represent an attractive alternative to preformed implants 
currently used in medicine (Packhaeuser et al., 2004). Of great interest are systems based on biodegradable 
polymers, such as linear polyesters of lactic and glycolic acid, approved by the FDA for parenteral use. This 
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polymer undergoes hydrolytic degradation to non-toxic monomers. Its degradation rate depends on: molecular 
weight, degree of crystallinity, comonomer composition and environmental conditions where degradation is 
taking place (Lewis, 1990). Hence, the degradation control is an important issue to be considered in the 
development of this kind of drug delivery platforms. 
For this purpose, we evaluated the in vitro and in vivo degradation of a PLGA implant formed in situ from 
a solution of PLGA and the biocompatible solvent DMSO. 
2. Materials and methods  
2.1. Polymer solution 
A polymer solution was prepared by mixing 0.3 g of PLGA (copolymer ratio 50:50, RG 502H, Boehringer 
Ingelheim) and 1 mL of DMSO until complete dissolution. PLGA implants were formed in situ by phase 
inversion (Graham et al., 1999). This precipitation process consists in the injection into an aqueous medium of 
a water insoluble polymer like PLGA dissolved in a water soluble solvent. The solvent diffuses out of the 
polymer while water diffuses into the polymer matrix. The polymer solidifies in contact with water, thus 
forming a solid polymeric implant.  
2.2. In vitro assay 
Several dialysis bags were filled with a volume of polymer solution equivalent to 75 mg of PLGA (M0). 
Bags were placed into glass flasks containing 10 mL of phosphate buffered saline solution (PBS; 0.1 M 
sodium phosphate, 0.15 M chloride sodium) pH 7.4 for the in situ implant formation. 
Glass flasks were incubated at 37 °C on a horizontal shaker at 50 rpm, for degradation assay of PLGA 
implants. The pH of the medium was measured every day. When the pH dropped to 7, the medium was 
replaced with fresh PBS, in order to keep the pH of the environment close to 7.4. Along 50 days, implants 
were withdrawn at predetermined time intervals, washed with distilled water, weighed (Mwet), vacuum-dried to 
constant weight (Mdry), and stored at -20 °C for further analysis. The study was conducted by duplicate. 
The Mass Loss and Water Content of the implants were calculated using the following equations: 
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On knowing the densities of water and PLGA at the temperature of the assay ( H2O, 37 °C = 
0.99337 g/mL), PLGA, 37 °C = 0.935965 g/mL), the Hollow Fraction was defined as: 
2
2
H O
H O PLGA
V
HollowFraction
V V
  (3) 
456   S. Boimvaser et al. /  Procedia Materials Science  1 ( 2012 )  454 – 460 
Eq. (3) assumes the absence of closed pores (all pores are interconnected), and a pore volume equal to the 
volume of water uptaken by the implant. This parameter refers to the water present not only inside the porous 
structure, but also inside the interstices between the polymer chains.  
For each implant we determined the weight average molecular weight (Mw) of PLGA by size exclusion 
chromatography (SEC) to study the degradation, and performed scanning electron microscopy (SEM) to 
assess their morphology. 
SEM photomicrographs were analyzed with an image processing program (ImageJ 1.40g). The pore size of 
the spongy matrix was determined by measuring both the pore diameter (expressed in m) and the pore area 
(expressed in m2). Adittionally, we determined the pore density (number of pores per unit of surface area, 
expressed in pores/mm2) and the relative porous area (area occupied by pores/total area·100). 
2.3. In vivo assay 
Volumes of the polymer solution corresponding to 75 mg of PLGA (M0) were injected subcutaneously into 
Wistar rats of 250-300 g for in situ implant formation. Rats were maintained in standard laboratory conditions. 
Implants were removed at different post injection times, dried under vacuum to constant weight (Mdry), and 
then stored at -20 °C for further analysis. The study was conducted by duplicate. 
Each implant was assesed to determine: Mass Loss according to Eq. (1), Mw by SEC, and morphology by 
SEM. In this case, besides the pore size, pore density, and relative porous area, we also measured the relative 
channel area (area occupied by channels/total area·100).  
A portion of the affected skin was removed, fixed in formol buffer and included in paraffin for 
histopathological evaluation. Animals tolerated well the PLGA solutions, since the inflammatory response at 
the implant site was mild and reversible, similar to that reported by other authors (Tang and Singh, 2009). 
2.4. Statistical analysis 
Data normality was evaluated on the basis of the Shapiro Wilks test. Results that presented a normal 
distribution were reported as mean value  standard deviation (SD). Results that did not present a normal 
distribution were reported as median and interquartile range (IR= quartile 1  quartile 3). The nonparametric 
Kruskal-Wallis test and the Mann-Whitney test allowed to find differences between several independent 
samples or to compare between pairs of independent samples, respectively. Samples were considered 
significantly different when p <0.01.  
3. Results and discussion 
Fig. 1 shows the in vitro evolution of the Mass Loss, Water Content, Hollow Fraction, and Mw of the 
implants. The Mass Loss rate was fairly constant during the assay, losing 85% of the mass at day 43. The 
Water uptake was important at the beginning of the experiment (77% at 1 day), and occurred mainly during 
the first three weeks where implants incorporated aproximately 90% of water. The time dependence of the 
Water Content rate (rWater Content) (inlet Fig. 1 b) clearly showed this result, where the rWater Content presented a 
gradual reduction until it reached a plateau. The Hollow Fraction against time is presented in Fig. 1 c. The 
increase observed involved the water gain and also the loss of mass in the polymer matrix, as it is defined by 
the Eq. (3). This may explain the similar behaviour observed between Water Content and Hollow Fraction 
(see Fig 1 b-c). It has been suggested not to use water to measure the pore volume of a copolymer when water 
swells the matrix (Yan et al., 2000), because part of the water tends to penetrate and relax the polymer matrix 
457 S. Boimvaser et al. /  Procedia Materials Science  1 ( 2012 )  454 – 460 
(Arifin et al., 2006). But in our definition of the Hollow Fraction we considered all the water gain, the one that 
occupies the porous structure and the one that swells the polymer.  
The PLGA implants presented a first period where the Mw decreased (Fig. 1d) until it reached an 
asymptotic value around 3800 g/mol up to day 50 of the degradation. 
 
 
Fig. 1. (a) Mass Loss; (b) Water Content; (c) Hollow Fraction; and (d) Mw of in situ formed implants during in vitro incubation time. 
Inlets Fig. 1 (b) and 1 (c) show the time depence of Water Content and Hollow Fraction rate. 
The Mass Loss and Mw of the implants during the in vivo assay are shown in Fig. 2. Similarly to the results 
in vitro, the Mass Loss rate was almost constant during the assay, but it reached a 90% loss at day 18. At day 
22 post injection, the mass of the implant was negligible. The half-life of in vivo implants was significantly 
shorter than that of in vitro implants, as reported in previous studies (Lu et al., 2000). The Mw of PLGA 
decreased rapidly during the first days up to 4000 g/mol. This value, similar to that achieved in vitro, was 
maintained until day 12. On day 18, the Mw decreased even more, reaching a value of 2000 g/mol. The fact 
that in vivo implants reached a much smaller Mw value than in vitro would probably be due to the hydrolytic 
action of immune cells and/or enzymes, which cleaved the polymer chains in smaller oligomeric units (Tracy 
et al., 1999). 
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Fig. 2. (a) Mass Loss; and (d) Mw of in situ formed implants during in vivo assay 
Fig. 3 and Fig. 4 show the sponge-like structure of the in situ formed implants and the changes of the 
morphology during the degradation study. Both in vitro and in vivo implants presented a continuos porous 
matrix with a large number of interconnected pores. Besides the pores, in vivo implants presented channels in 
its entire matrix. The structure of these implants was more compact, probably due to the pressure exerted by 
the skin during the precipitation process.  
 
 
Fig. 3. Photomicrographs of in situ forming implant degraded in vitro (scale bar: 10 m) 
 
Fig. 4. Photomicrographs of in situ forming implant degraded in vivo (scale bar: 10 m) 
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The structure of the pores changed during the degradation in vitro. Implants show spherical pores which 
size clearly increased from day 3 to 12 of the assay. At day 22 pores adquired a non-spherical shape, while 
after 33 days the amorphous structure of pores clearly showed an advanced erosional process (Fig. 3).  
On the in vivo assay, implants of day 3 and 12 post injection had similar structures. As degradation 
progressed, implants seemed to have a larger area occupied by channels and a greater ammount of very small 
pores.  
Table 1 shows the results of the photomicrographs analysis of in vitro and in vivo implants at different 
degradation times. 
 
Table 1. Photomicrographs analysis of in vitro and in vivo implants formed in situ. 
 In vitro In vivo 
 Day 3 Day 12 Day 22 Day 3 Day 12 
Pore area ( m2)a 64.1 (15.7-167.4) 141.5 (46.3-361.4) 140.9 (45.3-358.8) 6.9 (2.1-34.5) 2.4 (1.1-6.1) 
Pore diameter ( m)a 9.0 (4.5-14.6) 13.4 (7.7-21.5) -- 3.0 (1.6-6.6) 1.7 (1.2-2.8) 
Pore density 
(·103 pores/mm2)b 
20.2 (6.6) 14.2 (2.2) 5.5 (0.8) 10.6 (5.4) 40.5 (9.5) 
Relative porous area 
(pore area/total area·100)b 
86.2 (5.7) 70.4 (3.6) 65.5 (3.1) 37.9 (2.3) 31.7 (2.5) 
Relative channel area 
(channel area/total 
area·100)b 
-- -- -- 12.5 (1.1) 21.9 (3.7) 
a Results expressed as median (IR); b Results expressed as mean (SD) 
 
The pore size of the in vitro implants -measured as pore area and pore diameter- significantly increased 
from day 3 to day 12 of degradation. At day 22, pores maintained their size but acquired non-spherical 
structures. Therefore, in that case we measured the area and not the diameter. Quantification at day 33 was not 
possible due to the high degree of erosion.  
The pore area of in vivo implants significantly decreased from day 3 to day 12 post injection, related to the 
formation of new smaller pores. This phenomenon woul probably be associated to a degradation process more 
than an erosional process. 
The pore area of the implants increased in vitro, while it decreased in vivo. Conversely, this difference is 
reflected in the pore density. This parameter decreased in vitro due to an increase in pore size, while it 
increased in vivo because of the appearance of large number of small pores. 
As degradation time progressed, relative porous area decreased both in vitro and in vivo. These differences 
are not statistically significant but they can be appreciated in Fig. 3., where pores start to fuse together and 
their structures are not easily differentiated. Furthermore, the area occupied by channels (relative channel 
area) in the in vivo implants increased from day 3 to day 12 of degradation. 
Channels of in vivo implants probably allowed physiological fluids to flow through the polymer matrix, 
maintaining the pH and preventing the accumulation of degradation products that could be exerting an 
autocatalytic effect. This physiological condition was simulated in vitro by making a rigurous control of the 
pH of the medium and replacing the buffer every time it dropped to 7.0. Otherwise, in vivo channels may 
facilitate degradation by increasing the contact surface area with aqueous fluids and allowing the entrance of 
hydrolytic enzymes and immune system cells to the entire matrix. 
460   S. Boimvaser et al. /  Procedia Materials Science  1 ( 2012 )  454 – 460 
Morphological changes observed in vitro during degradation were associated to an increase in pore size and 
a decrease in its density, while in vivo they were associated to the appearance of many new tinny pores and an 
increase of the area occupied by channels. 
 
4. Conclusions 
Experimental results clearly show that an in vitro-in vivo correlation is not straightforward. Channels 
observed in the implants formed in vivo probably prevented the accumulation of degradation products that 
could lead to an autocatalytic effect. But on the other hand, they increased the contact with aqueous fluids, 
which in turns facilites the access of hydrolytic enzymes and immune system cells to the whole implant. This 
would explain the shorter degradation time of the implants degraded in vivo. These outcomes highlight the 
importance of the biological mechanisms involved in the degradation of PLGA implants. 
Acknowledgements 
The author made this work in memory of Dr. Ricardo J.A. Grau and Dra. Ma. Inés Cabrera, who passed 
away while this paper was being done. Moreover, the author wish to thank to Agencia Nacional de Promoción 
Científica y Tecnológica (ANPCYT), Consejo Nacional de Investigaciones Científicas y Técnicas 
(CONICET), and Universidad Nacional del Litoral (UNL) of Argentina, for the financial support granted to 
this contribution. 
References 
Arifin, D.Y., Lee, L.Y., Wang, C.H., 2006. Mathematical modeling and simulation of drug release from microspheres: Implications to 
drug delivery systems, Advanced Drug Delivery Reviews 58, p. 1274. 
Graham, P.D., Brodbeck, K.J., McHugh, A.J., 1999. Phase inversion dynamics of PLGA solutions related to drug delivery, Journal of 
Controlled Release 58, p. 233. 
Lewis, D.H., 1990. Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers, in 
Delivery Systems  Chasin M., Langer R., Editors. Marcel Dekker, Inc., New York, p. 3. 
Lu, L., Peter, S.J., Lyman, M.D., Lai, H.L., Leite, S.M., Tamada, J.A., Uyama, S., Vacanti, J.P., Langer, R., Mikos, A.G., 2000. In vitro 
and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams, Biomaterials 2, p. 1837 
Packhaeuser, C.B., Schnieders, J., Oster, C.G., Kissel, T., 2004. In situ forming parenteral drug delivery systems: an overview, European 
Journal of Pharmaceutics and Biopharmaceutics 58(2), p. 445. 
Tang, Y., Singh, J., 2009. Biodegradable and biocompatible thermosensitive polymer based injectable implant for controlled release of 
protein, International Journal of Pharmaceutics 365(1-2). p. 34. 
Tracy, M.A., Ward, K.L., Firouzabadian, L., Wang, Y., Dong, N., Qian, R. and Zhang, Y., 1999. Factors affecting the degradation rate of 
poly(lactide-co-glycolide) microspheres in vivo and in vitro, Biomaterials 20, p. 1057 
Yan, J., Wang, X., Yang Y., 2000. Water uptake and pore volume determination of porous styrene divinylbenzene copolymers, Reactive 
& Functional Polymers 43, p. 227. 
. 
 
